Reports

Ideas That Generate Results

Global Cancer Generics Market Forecast to 2022

Global Cancer Generics Market Forecast to 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Oct, 2016| No. of Pages : 110

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1400.00
CD-ROM Mail Delivery
US$ 1600.00
Hard Copy Mail Delivery
US$ 1600.00
Electronic Access - Multi-User License
US$ 2000.00
List of Figures:
 
Figure 3-1: Global - Cancer Incidences (Million), 2015 & 2025
Figure 3-2: Global - Cancer Incidences by Gender (Million), 2015
Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2016 & 2022
Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030 
Figure 4-3: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 5-1: Global - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 6-1: Global - Cancer Generics Market by Mode of Administration (%), 2016
Figure 7-1: Global - Cancer Generics Market by Major Indications (%), 2016
Figure 7-2: Global - Lung Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-3: Global -Lung Cancer Incidences (Million), 2015 & 2025
Figure 7-4: Global - Breast Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-5: Global -Breast Cancer Incidences (Million), 2015 & 2025
Figure 7-6: Global - Colorectal Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-7: Global -Colorectal Cancer Incidences (Million), 2015 & 2025
Figure 7-8: Global - Stomach Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-9: Global -Stomach Cancer Incidences (Million), 2015 & 2025
Figure 7-10: Global - Prostate Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-11: Global -Prostate Cancer Incidences (Million), 2015 & 2025
Figure 8-1: Global - Cancer Generics Market by Geographic Regions (%), 2016
Figure 8-2: US - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-3: US - Cancer Incidences (Million), 2015 & 2025
Figure 8-4: Europe - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-5: Europe - Cancer Incidences (Million), 2015 & 2025
Figure 8-6: Asia-Pacific - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-7: Asia-Pacific - Cancer Incidences (Million), 2015 & 2025
Figure 11-1: Fresenius Kabi AG - Sales by Product Segment (%), 2015
Figure 11-2: Fresenius Kabi AG - Sales by Geographic Region (%), 2015
Figure 11-3: Pfizer Inc - Revenue by Business Segment (%), 2015
Figure 11-4: Pfizer Inc - Revenue by Geographic Region (%), 2015
Figure 11-5: Teva Pharmaceutical - Revenue by Business Segment (%), 2015
Figure 11-6: Teva Pharmaceutical - Revenue by Geographic Region (%), 2015
Figure 11-7: Mylan N.V. - Revenue by Business Segment (%), 2015
Figure 11-8: Mylan N.V. - Revenue by Geographic Region (%), 2015
Figure 11-9: Sun Pharmaceutical - Total Income by Business Segment (%), FY 2016
Figure 11-10: Sun Pharmaceutical - Total Income by Geographic Region (%), FY 2016
Figure 11-11: Sandoz International GmbH - Net Sales by Franchise (%), 2015
Figure 11-12: Sanofi - Sales by Business Segment (%), 2015
Figure 11-13: Sanofi - Sales by Geographic Region (%), 2015
Figure 11-14: Dr. Reddy's Laboratories - Revenue by Business Segment (%), FY 2016
Figure 11-15: Dr. Reddy's Laboratories - Revenue by Geographic Region (%), FY 2016
Figure 11-16: Cipla Ltd. - Revenue by Geographic Region (%), FY 2016
 
List of Tables:
 
Table 3-1: Most Prevalent Types of Cancer, 2015
Table 4-1: Global - Key Cancer Drugs and Patent Expiry Status
Table 6-1: List of Companies Dealing in Generic Arimidex
Table 6-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 6-3: List of Companies Dealing in Generic Femara
Table 6-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 6-5: List of Companies Dealing in Generic Hycamtin
Table 6-6: List of Companies Dealing in Generic Xeloda
Table 6-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 6-8: List of Companies Dealing in Generic Gleevec
Table 6-9: Cost Comparison of Generics and Branded Gleevec (Imatinib Mesylate)
Table 6-10: List of Companies Dealing in Generic Nolvadex
Table 6-11: Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
Table 6-12: List of Companies Dealing in Generic Targretin
Table 6-13: List of Companies Dealing in Generic Camptosar
Table 6-14: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 6-15: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 6-16: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 6-17: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 6-18: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 6-19: List of Companies Dealing in Generic Platinol (Cisplatin)
Table 6-20: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 6-21: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 6-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 6-23: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-24: List of Companies Dealing in Generic Fusilev (Levoleucovorin)
Table 6-25: List of Companies Dealing in Generic Ellence (Epirubicin Hydrochloride)
Table 6-26: List of Companies Dealing in Generic Adriamycin (Doxorubicin Hydrochloride)
Table 7-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 7-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 7-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 7-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 7-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 10-1: Global - Major M&A in the Generics Industry (2014-2016)
Table 11-1: Fresenius Kabi AG - Sales (Billion US$), 2013, 2014 & 2015
Table 11-2: Fresenius Kabi Pharmaceuticals - Key Cancer Generic Drugs
Table 11-3: Pfizer Inc - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-4: Pfizer Inc - Key Cancer Generic Products
Table 11-5: Teva Pharmaceutical - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-6: Teva Pharmaceutical - Key Cancer Generic Drugs
Table 11-7: Mylan N.V. - Revenue (Billion US$), 2013, 2014 & 2015
Table 11-8: Mylan N.V. - Key Cancer Generic Drugs
Table 11-9: Sun Pharmaceutical - Total Income (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-10: Sun Pharmaceutical - Key Cancer Generic Drugs
Table 11-11: Sandoz International GmbH - Sales (Billion US$), 2013, 2014 & 2015
Table 11-12: Sandoz International GmbH - Key Cancer Generic Drugs
Table 11-13: Sanofi - Net Sales (Billion US$), 2013, 2014 & 2015
Table 11-14: Sanofi - Key Cancer Generic Drugs
Table 11-15: Dr. Reddy's Laboratories - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-16: Dr. Reddy's Laboratories - Key Cancer Generic Drugs
Table 11-17: Cipla Ltd. - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 11-18: Cipla Ltd. - Key Cancer Generic Drugs
Table 11-19: Apotex Inc. - Key Cancer Generic Drugs
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.